Who Paid My Doc
Stefan Renaud
Orthopaedic Surgery Charlotte, NC Doctor of Osteopathy
NPI 1174736599 CMS profile 189212
4601 Park Rd, Ste 300, Charlotte, NC 28209
General payments
$185,323
Research payments
$0
Ownership & investment interest
$1,373,201
Through program year 2025, Stefan Renaud of Charlotte, NC is reported in the CMS Open Payments database as having received $185,323 across 211 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $1,373,201 across 18 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 94th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
14 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $28,588 | 36 | |
| 2024 | General | $54,677 | 27 | |
| 2023 | General | $13,183 | 37 | |
| 2022 | General | $15,320 | 35 | |
| 2021 | General | $12,200 | 12 | |
| 2020 | General | $15,895 | 16 | |
| 2019 | General | $45,460 | 48 | |
| 2025 | Ownership | $136,529 | 2 | |
| 2024 | Ownership | $111,598 | 2 | |
| 2023 | Ownership | $161,598 | 3 | |
| 2022 | Ownership | $156,849 | 3 | |
| 2021 | Ownership | $290,173 | 3 | |
| 2020 | Ownership | $290,885 | 3 | |
| 2019 | Ownership | $225,570 | 2 |
Beside peers
- Stefan Renaud
- Orthopaedic Surgery median
- Middle half of Orthopaedic Surgery
- National median
In program year 2025, general payments to Stefan Renaud were reported at $28,588. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.
Show as a table
| Year | Stefan Renaud | Orthopaedic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $45,460 | $644 | $140–$2,844 | $163 |
| 2020 | $15,895 | $312 | $75–$1,860 | $114 |
| 2021 | $12,200 | $520 | $117–$2,495 | $132 |
| 2022 | $15,320 | $598 | $128–$2,731 | $149 |
| 2023 | $13,183 | $461 | $128–$2,264 | $160 |
| 2024 | $54,677 | $497 | $134–$2,475 | $164 |
| 2025 | $28,588 | $563 | $147–$2,717 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
529
Drug cost
$4,207
Branded share of claims
25%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 71 | $786 | |
| Clindamycin Hcl | Generic | 89 | $562 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 47 | $530 | |
| Gabapentin | Generic | 49 | $510 | |
| Prednisone | Generic | 48 | $416 | |
| Pregabalin | Generic | 27 | $299 | |
| Celecoxib | Generic | 20 | $292 | |
| Ketorolac Tromethamine | Generic | 21 | $239 | |
| Tramadol Hcl | Generic | 55 | $196 | |
| Tizanidine Hcl | Generic | 31 | $122 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 94 billing codesPaid by Medicare
$167,463
Medicare patients
262
Services billed
1,806
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 39% | |
| Chronic kidney disease | 32% | |
| Depression | 31% | |
| Ischemic heart disease | 27% | |
| Osteoporosis | 22% | |
| Heart failure | 19% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 33 | 304 | $236 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 21 | 420 | $37 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 22 | 118 | $13 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
211 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Surgery in North Carolina
Related records
Orthopaedic Surgery in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.